drugset / Trial / NCT01951924

LIME Study (LFB IVIg MMN Efficacy Study)

NCT01951924

Phase 3 Completed 23 enrolled LFB TFS Trial Form Support · collab
RandomizedCrossoverQuadruple-blindTreatment

Summary

The aim of this study is to evaluate the efficacy and safety of I10E (LFB 10% ready-to-use liquid human intravenous immunoglobulin) compared to Kiovig® for the maintenance treatment of MMN in a randomized, double-blind, active comparator-controlled, cross-over trial.

Timeline

Start
2013-12
Primary completion
2016-07
Completion
2016-07

Drugs

EvaluationDrugModalityDoseRoute
Subject I10E Protein / enzyme biologic 1 g/kg Intravenous
Subject I10E Protein / enzyme biologic 2 g/kg Intravenous
Subject Immune Globulin Intravenous (Human) Protein / enzyme biologic 1 g/kg Intravenous
Subject Immune Globulin Intravenous (Human) Protein / enzyme biologic 2 g/kg Intravenous

Indications